Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
Arch Venture Partners
AlphaWeek Category
Venture Capital
Last Updated
07/10/2022
Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
Hillhouse Capital Leads Hangzhou Just Biotherapeutics Series B+
Participation by existing investors Temasek, Lilly Asia Ventures (LAV), ARCH Venture Partners, Taikang and BOCGI Zheshang Capital
AlphaWeek’s Upcoming Events
-
New York October 18, 2023
-
New York October 19, 2023
Editor’s Choice
-
Hedge Funds / May 15, 2023
-
Hedge Funds / Apr 13, 2023
AlphaWeek Alert
Most Popular
